Skip to main content

Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.

Publication ,  Journal Article
Feuerlein, S; Boll, DT; Gupta, RT; Ringe, KI; Marin, D; Merkle, EM
Published in: AJR Am J Roentgenol
January 2011

OBJECTIVE: The purpose of this study was to investigate the relative enhancement characteristics of the hepatic parenchyma and portal vein during gadoxetate disodium-enhanced abdominal MRI and to assess whether contrast between the portal vein and the hepatic parenchyma can be improved with higher doses of gadoxetate disodium. MATERIALS AND METHODS: A total of 102 patients (61 women, 41 men) underwent gadoxetate disodium-enhanced abdominal MRI. They received a weight-independent dose of 10 mL of gadoxetate disodium, corresponding to a dose spectrum of 0.02-0.06 mmol/kg body weight. The patients were assigned to one of three dose groups: recommended dose (0.02-0.03 mmol/kg), intermediate dose (0.03-0.045 mmol/kg), or high dose (0.045-0.06 mmol/kg). The signal-to-noise ratios for the portal vein, liver, and the portal vein-to-liver contrast-to-noise ratio were calculated for three consecutive arterial phases, one portal venous phase, and four delayed imaging phases. RESULTS: The delayed phase images of the liver showed statistically significant dose dependency and greater enhancement in the intermediate- and high-dose groups (p < 0.01). Analogously, the portal vein also exhibited greater enhancement in the two higher-dose groups, but the difference was not statistically significant (p > 0.05). Regarding portal vein-to-liver contrast, all three groups had a dose-independent fast parallel increase from baseline toward maximum contrast followed by a steady decline in contrast with no statistically significant differences between dose groups (p > 0.05). CONCLUSION: Portal vein-to-liver contrast during gadoxetate disodium-enhanced hepatic MRI cannot be improved within a dose spectrum of 0.025-0.06 mmol/kg body weight.

Duke Scholars

Published In

AJR Am J Roentgenol

DOI

EISSN

1546-3141

Publication Date

January 2011

Volume

196

Issue

1

Start / End Page

W18 / W24

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Portal Vein
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Liver Function Tests
  • Liver Diseases
  • Linear Models
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Feuerlein, S., Boll, D. T., Gupta, R. T., Ringe, K. I., Marin, D., & Merkle, E. M. (2011). Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein. AJR Am J Roentgenol, 196(1), W18–W24. https://doi.org/10.2214/AJR.10.4387
Feuerlein, Sebastian, Daniel T. Boll, Rajan T. Gupta, Kristina I. Ringe, Daniele Marin, and Elmar M. Merkle. “Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.AJR Am J Roentgenol 196, no. 1 (January 2011): W18–24. https://doi.org/10.2214/AJR.10.4387.
Feuerlein S, Boll DT, Gupta RT, Ringe KI, Marin D, Merkle EM. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein. AJR Am J Roentgenol. 2011 Jan;196(1):W18–24.
Feuerlein, Sebastian, et al. “Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.AJR Am J Roentgenol, vol. 196, no. 1, Jan. 2011, pp. W18–24. Pubmed, doi:10.2214/AJR.10.4387.
Feuerlein S, Boll DT, Gupta RT, Ringe KI, Marin D, Merkle EM. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein. AJR Am J Roentgenol. 2011 Jan;196(1):W18–W24.

Published In

AJR Am J Roentgenol

DOI

EISSN

1546-3141

Publication Date

January 2011

Volume

196

Issue

1

Start / End Page

W18 / W24

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Portal Vein
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Liver Function Tests
  • Liver Diseases
  • Linear Models
  • Humans